These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 35909272)

  • 1. BNT162b2 Elicited an Efficient Humoral Response Against Different Strains of SARS-CoV-2 in People Living with HIV.
    Gidari A; Bastianelli S; Pierucci S; Busti C; Sabbatini S; Schiaroli E; Benedetti S; Gamboni G; Lanzi A; Francisci D
    Curr HIV Res; 2022; 20(4):296-300. PubMed ID: 35909272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count.
    Antinori A; Cicalini S; Meschi S; Bordoni V; Lorenzini P; Vergori A; Lanini S; De Pascale L; Matusali G; Mariotti D; Cozzi Lepri A; Gallì P; Pinnetti C; Gagliardini R; Mazzotta V; Mastrorosa I; Grisetti S; Colavita F; Cimini E; Grilli E; Bellagamba R; Lapa D; Sacchi A; Marani A; Cerini C; Candela C; Fusto M; Puro V; Castilletti C; Agrati C; Girardi E; Vaia F;
    Clin Infect Dis; 2022 Aug; 75(1):e552-e563. PubMed ID: 35366316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humoral immune response following prime and boost BNT162b2 vaccination in people living with HIV on antiretroviral therapy.
    Jedicke N; Stankov MV; Cossmann A; Dopfer-Jablonka A; Knuth C; Ahrenstorf G; Ramos GM; Behrens GMN
    HIV Med; 2022 May; 23(5):558-563. PubMed ID: 34725907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-neutralization of SARS-CoV-2 B.1.1.7 and P.1 variants in vaccinated, convalescent and P.1 infected.
    Gidari A; Sabbatini S; Bastianelli S; Pierucci S; Busti C; Monari C; Luciani Pasqua B; Dragoni F; Schiaroli E; Zazzi M; Francisci D
    J Infect; 2021 Oct; 83(4):467-472. PubMed ID: 34320390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Humoral and Cellular Immune Response Elicited by Two Doses of mRNA BNT162b2 Vaccine Against SARS-CoV-2 in People Living with HIV.
    Vanetti C; Milazzo L; Ardizzone F; Oreni L; Cappelletti G; Trabattoni D; Biasin M
    AIDS Res Hum Retroviruses; 2023 Sep; 39(9):495-499. PubMed ID: 37031355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1.
    Levy I; Wieder-Finesod A; Litchevsky V; Biber A; Indenbaum V; Olmer L; Huppert A; Mor O; Goldstein M; Levin EG; Hod T; Cohen C; Lustig Y; Rahav G
    Clin Microbiol Infect; 2021 Dec; 27(12):1851-1855. PubMed ID: 34438069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced neutralizing antibody response to SARS-CoV-2 vaccine booster dose in people living with HIV with severe immunosuppression.
    Corma-Gómez A; Fernández-Fuertes M; Viñuela L; Domínguez C; Santos M; Fuentes-López A; Rojas A; Fernández-Pérez N; Martín-Carmona J; Serrano-Conde E; Real LM; Mendoza J; Macías J; Pineda JA; García F
    J Med Virol; 2023 Mar; 95(3):e28602. PubMed ID: 36880164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inactivated SARS-CoV-2 vaccines elicit immunogenicity and T-cell responses in people living with HIV.
    Lv Z; Li Q; Feng Z; Zheng X; NaYin ; Yang H; Gu Q; Ying S; Qi Y; Li X; Wu R; Wu Z; Yu X; Zou N; Qin D; Wan C
    Int Immunopharmacol; 2022 Jan; 102():108383. PubMed ID: 34824035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe immunosuppression is related to poorer immunogenicity to SARS-CoV-2 vaccines among people living with HIV.
    Corma-Gómez A; Fernández-Fuertes M; García E; Fuentes-López A; Gómez-Ayerbe C; Rivero-Juárez A; Domínguez C; Santos M; Viñuela L; Palacios R; Real LM; Rivero A; Macías J; Pineda JA; García F
    Clin Microbiol Infect; 2022 Nov; 28(11):1492-1498. PubMed ID: 35640840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does COVID-19 Vaccination with BNT162b2 Influence HIV-Related Immunological and Virological Markers? Data from 235 Persons Living with HIV at Cotugno Hospital, Naples, Italy: Immune Response After Second and Third Doses, and Influence on Immunovirological Markers.
    Fusco FM; Carleo MA; Sangiovanni N; D'Abbraccio M; Tambaro O; Borrelli F; Viglietti R; Camaioni C; Bruner V; Falanga R; Pisapia R; Palmiero G; Rizzo V; Rosario P; Cuomo N; Spatarella M; Esposito V; Sangiovanni V
    Viral Immunol; 2023 Jun; 36(5):360-365. PubMed ID: 37140991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relatively preserved functional immune capacity with standard COVID-19 vaccine regimen in people living with HIV.
    Hung CY; Hsiao SH; Huang CG; Chang CS; Chen GY; Huang YL; Dutta A; Huang CT
    Front Immunol; 2023; 14():1204314. PubMed ID: 37731482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living With Human Immunodeficiency Virus (HIV).
    Woldemeskel BA; Karaba AH; Garliss CC; Beck EJ; Wang KH; Laeyendecker O; Cox AL; Blankson JN
    Clin Infect Dis; 2022 Apr; 74(7):1268-1270. PubMed ID: 34293114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in Post-mRNA Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Immunoglobulin G (IgG) Concentrations and Surrogate Virus Neutralization Test Response by Human Immunodeficiency Virus (HIV) Status and Type of Vaccine: A Matched Case-Control Observational Study.
    Spinelli MA; Peluso MJ; Lynch KL; Yun C; Glidden DV; Henrich TJ; Deeks SG; Gandhi M
    Clin Infect Dis; 2022 Aug; 75(1):e916-e919. PubMed ID: 34864962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody Response in Immunocompromised Patients After the Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine BNT162b2 or mRNA-1273: A Randomized Controlled Trial.
    Speich B; Chammartin F; Abela IA; Amico P; Stoeckle MP; Eichenberger AL; Hasse B; Braun DL; Schuurmans MM; Müller TF; Tamm M; Audigé A; Mueller NJ; Rauch A; Günthard HF; Koller MT; Trkola A; Briel M; Kusejko K; Bucher HC;
    Clin Infect Dis; 2022 Aug; 75(1):e585-e593. PubMed ID: 35234868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralization of SARS-CoV-2 Variants by Serum from BNT162b2 Vaccine Recipients.
    Valleriani F; Mancuso E; Vincifori G; Teodori L; Di Marcantonio L; Spedicato M; Leone A; Savini G; Morelli D; Bonfini B; Lorusso A
    Viruses; 2021 Oct; 13(10):. PubMed ID: 34696441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of Serum and Mucosal SARS-CoV-2-Antibodies in HIV-1-Infected Subjects after BNT162b2 mRNA Vaccination or SARS-CoV-2 Infection.
    Schmidt KG; Harrer EG; Tascilar K; Kübel S; El Kenz B; Hartmann F; Simon D; Schett G; Nganou-Makamdop K; Harrer T
    Viruses; 2022 Mar; 14(3):. PubMed ID: 35337058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2 vaccine immunogenicity for people living with HIV: A systematic review and meta-analysis.
    Søndergaard MH; Thavarajah JJ; Churchill Henson H; Wejse CM
    HIV Med; 2024 Jan; 25(1):16-37. PubMed ID: 37731375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study.
    Lasagna A; Bergami F; Lilleri D; Percivalle E; Quaccini M; Alessio N; Comolli G; Sarasini A; Sammartino JC; Ferrari A; Arena F; Secondino S; Cicognini D; Schiavo R; Lo Cascio G; Cavanna L; Baldanti F; Pedrazzoli P; Cassaniti I
    ESMO Open; 2022 Apr; 7(2):100458. PubMed ID: 35427842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differing kinetics of anti-spike protein IgGs and neutralizing antibodies against SARS-CoV-2 after Comirnaty (BNT162b2) immunization.
    Bonura F; De Grazia S; Bonura C; Sanfilippo GL; Giammanco GM; Amodio E; Ferraro D
    J Appl Microbiol; 2022 May; 132(5):3987-3994. PubMed ID: 35083832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impaired Functional T-Cell Response to SARS-CoV-2 After Two Doses of BNT162b2 mRNA Vaccine in Older People.
    Demaret J; Corroyer-Simovic B; Alidjinou EK; Goffard A; Trauet J; Miczek S; Vuotto F; Dendooven A; Huvent-Grelle D; Podvin J; Dreuil D; Faure K; Deplanque D; Bocket L; Duhamel A; Labreuche J; Sobaszek A; Hisbergues M; Puisieux F; Labalette M; Lefèvre G
    Front Immunol; 2021; 12():778679. PubMed ID: 34868051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.